Difference between revisions of "Team:Tel-Hai"

 
(18 intermediate revisions by 2 users not shown)
Line 1: Line 1:
−
<html>
+
<html><link rel="stylesheet" type="text/css" href="https://2016.igem.org/Template:Tel-Hai/CSS?action=raw&ctype=text/css" />
−
<link rel="stylesheet" type="text/css" href="https://2016.igem.org/Template:Tel-Hai/CSS?action=raw&ctype=text/css" />
+
<img id="topimg" src="https://static.igem.org/mediawiki/2016/8/8b/T--Tel-Hai--dna.jpg" />
 +
</html> {{Team:Tel-Hai/Header}} <html>
 +
<br>
 +
<br>
 +
<br>
 +
<br>
 +
<br>
  
  
 +
<p style="text-align: center; margin: 2em 0;">
 +
  <video src="https://static.igem.org/mediawiki/2016/7/79/T--Tel-Hai--video.mp4" style="max-width: 85%;" controls />
 +
</p>
  
−
<img id="topimg" src="https://static.igem.org/mediawiki/2016/8/8b/T--Tel-Hai--dna.jpg" />
+
<div class="space-equally">
 +
<div class="flip-container" ontouchstart="this.classList.toggle('hover');">
 +
  <div class="flipper"><div class="front">
 +
      <h3><span>Where</span> is the magic happening?</h3>
 +
    </div><div class="back">
 +
      <p>Tel-Hai and MIGAL's labs located in northen Israel</h3>
 +
    </div>
 +
</div></div>
  
−
<div id="pageContainer">
 
  
−
<header>
+
<div class="flip-container" ontouchstart="this.classList.toggle('hover');">
−
<nav>
+
  <div class="flipper"><div class="front">
−
<ul id="menu-nav">
+
      <h3><span>Who</span> are we?</h3>
−
<li><a href="https://2016.igem.org/wiki/index.php?title=Team:Tel-Hai">Project</a></li>
+
    </div><div class="back">
−
<li><a href="#">Team</a>
+
      <p>Group of dedicated students and researchers from the fields of biotechnology and biochemistry</p>
−
<ul>
+
    </div>
−
<li><a href="#">The Team</a></li>
+
</div></div>
−
<li><a href="#">Attributions</a></li>
+
−
</ul>
+
−
</li>
+
−
<li><a href="#">Notebook</a></li>
+
  
−
<li><a href="#">Protocols</a></li>
 
−
<li><a href="#">Entrepreneurship</a></li>
 
−
</ul>
 
−
<nav>
 
−
<h2><span>i</span>GEM Tel-Hai 2016</h2>
 
−
</header>
 
  
−
<h3>Introduction</h3>
+
<div class="flip-container" ontouchstart="this.classList.toggle('hover');">
−
<div class="sideBox">
+
  <div class="flipper"><div class="front">
 +
      <h3><span>What</span> is our goal?</h3>
 +
    </div><div class="back">
 +
      <p>Correcting the most prevalent mutation in the CFTR protein, causing Cystic Fibrosis, in somatic cells</p>
 +
    </div>
 +
</div></div>
  
  
 +
<div class="flip-container" ontouchstart="this.classList.toggle('hover');">
 +
  <div class="flipper"><div class="front">
 +
      <h3><span>Why</span> did we choose Cystic Fibrosis?</h3>
 +
    </div><div class="back">
 +
      <p>This is a "simple" missense mutation, leading to the loss of single amino acid, causing Cystic Fibrosis - a largely researched lethal genetic disease, found in every ethnic group world-wide.</p>
 +
    </div>
 +
</div></div>
  
  
−
<blockquote>
+
<div class="flip-container" ontouchstart="this.classList.toggle('hover');">
−
<p>The CFTR gene encodes an ATP-binding cassette (ABC) transporter that functions as a low conductance Cl(-)-selective channel gated by cycles of ATP binding and hydrolysis at its nucleotide-binding domains (NBDs) and regulated tightly by an intrinsically disordered protein segment distinguished by multiple consensus phosphorylation sites termed the regulatory domain</p>
+
  <div class="flipper"><div class="front">
−
<footer>
+
      <h3><span>Why now</span> of all times?</h3>
−
— <cite>Summary by Wang et al., 2014</cite>
+
    </div><div class="back">
−
</footer>
+
      <p>Only recently has genome editing become an affordable and practical tool for <strong>all researchers</strong>, to maximize efficiency in correcting diseases causing mutations.</p>
−
</blockquote>
+
    </div>
 +
</div></div>
  
 +
 +
<div class="flip-container" ontouchstart="this.classList.toggle('hover');">
 +
  <div class="flipper"><div class="front">
 +
      <h3><span>How</span> can we do it?</h3>
 +
    </div><div class="back">
 +
      <p>Utilizing the Cholera toxin's non-toxic B Sub-unit as a delivery system for a plasmid containing a CRISPR/Cas9 apparatus, so as to specifically correct the defected DNA fragment with minimal collateral damage.</p>
 +
    </div>
 +
</div></div>
 
</div>
 
</div>
−
<p>Cystic fibrosis (CF) is the most common lethal genetic disorder in Caucasian populations. It affects mostly the lungs, and also the pancreas, liver and kidneys. The CF disorder is a result of mutations in a gene coding for an ATP-gated ion channel called cystic fibrosis trans membrane conductance regulator - CFTR. Nearly two thousand cystic fibrosis causing mutations in the CFTR gene have been described. The most common mutation is ΔF508, which results from a deletion of three nucleotides, and a consequent loss of the amino acid phenylalanine. A CFTRΔF508 protein is unable to leave the endoplasmic reticulum (ER) and translocate to the plasma membrane.</p>
 
  
−
<p>There is yet no cure for cystic fibrosis, and today CF patients suffering lung infections are treated with antibiotics. Excessive mucus blocking the lungs is removed by mucus thinning drugs and physical exercises. Previous research has demonstrated that the CRISPR technology has the potential to provide a successful treatment for CF. However; this potential has not yet been realized due to the lack of an efficient delivery vehicle which can specifically target, in vivo, the epithelium of the airways and lungs. Therefore, we wish to suggest a new way of targeting the CRISPR components in order to fix the ΔF508 mutation, as described below.</p>
 
  
−
<h3>Project Description</h3>
+
</div></html>
−
<p>The B subunit of the toxin produced by the pathogenic bacterium Vibrio cholera can specifically bind the GM1-like ganglioside receptor on the membrane of epithelial cells – including the asialo-GM1 variant that line the lungs. This binding leads to internalization of the toxin by endocytosis. We, therefore, intend to use this B subunit as a vehicle to specifically deliver the CRISPR/Cas9 expression plasmid into the epithelium of the lungs of CF patients. The CRISPR/Cas9 plasmid will be attached to the B subunit by a cleavable linker and the conjugated molecules will be applied by aerosol spray to the nose. A special “repair template”, designed to replace the ΔF508 mutation by the correct sequence (via homology directed repair - HDR) will also be delivered into the cells by this B subunit in a similar way. Both DNA molecules will be delivered as naked DNA.</p>
+
−
 
+
−
<p style="text-align: center; margin-top: 2em;">
+
−
  <video src="https://static.igem.org/mediawiki/2016/7/79/T--Tel-Hai--video.mp4" style="max-width: 85%;" controls />
+
−
</p>
+
−
 
+
−
</div>
+
−
</html>
+

Latest revision as of 22:30, 19 October 2016

iGEM Tel-Hai 2016






Where is the magic happening?

Tel-Hai and MIGAL's labs located in northen Israel

Who are we?

Group of dedicated students and researchers from the fields of biotechnology and biochemistry

What is our goal?

Correcting the most prevalent mutation in the CFTR protein, causing Cystic Fibrosis, in somatic cells

Why did we choose Cystic Fibrosis?

This is a "simple" missense mutation, leading to the loss of single amino acid, causing Cystic Fibrosis - a largely researched lethal genetic disease, found in every ethnic group world-wide.

Why now of all times?

Only recently has genome editing become an affordable and practical tool for all researchers, to maximize efficiency in correcting diseases causing mutations.

How can we do it?

Utilizing the Cholera toxin's non-toxic B Sub-unit as a delivery system for a plasmid containing a CRISPR/Cas9 apparatus, so as to specifically correct the defected DNA fragment with minimal collateral damage.